Incidence of bone metastases in different cancers.
Abstract
Bone metastases are more common than primary bone cancers, especially in adults. Bone is the third most common organ affected by metastases, from many types of solid cancers but especially those arising in the breast and prostate. Besides the impact on survival, bone metastases may have a big impact on morbidity and represents a significant healthcare burden. Skeletal-related events (SREs) include pain, pathologic fracture, spinal cord compression, and hypercalcemia and can cause a deterioration of the quality of life. Detection of bone metastases is essential for accurate staging and optimal treatment; however, there is no consensus or standard approach for diagnosis, so the choice of imaging should be guided by clinical presentation. Treatment goals may consist of controlling pain and other symptoms, preserving and restoring function, minimizing the risk of SREs, stabilizing the skeleton, and enhancing local tumor control. Therapeutic options include pain management/analgesia, osteoclast inhibitors, systemic anticancer therapy, radiation therapy, bone-targeting radiopharmaceutical therapy, surgery, and/or image-guided thermal ablation. The choice of treatment is influenced by factors like symptoms, impact on quality of life, performance status, estimated life expectancy, goals of treatment, and preferences of care.
Keywords
- bone metastases
- cancer pain
- osteoclast inhibitors
- bisphosphonates
- denosumab
1. Introduction
Bone metastases are more common than primary bone cancers, especially in adults [1]. Bone is the third most common organ affected by metastases, from many types of solid cancers but especially those arising in the breast and prostate [1, 2, 3]. The most common locations for metastatic disease are the vertebral column, sacrum, pelvis, and proximal femurs [4].
The overall incidence of bone metastases is not known [1, 2]. It is estimated to have an incidence in about 70% of patients with breast and prostate cancer, which are the two most common cancers worldwide, but bone metastases can occur in a wide range of malignancies, described in Table 1 [2, 3, 5].
Primary tumor | Incidence of bone metastases (%) |
---|---|
Breast cancer | 65–75 |
Prostate cancer | 65–75 |
Thyroid cancer | 40–60 |
Bladder cancer | 40 |
Lung cancer | 30–40 |
Renal cell carcinoma | 20–35 |
Melanoma | 15–45 |
Gastrointestinal cancer | 5 |
In terms of prognosis, survival varies according to the tumor type, with the median survival of patients with breast and prostate cancer reaching years and of patients with lung cancer being measured in months, and it is also influenced by coexisting non-osseous metastatic disease, which ends up being important in determining the prognosis [3]. However, bone metastases may have a big impact on morbidity and represents a significant healthcare burden [3, 6].
2. Mechanism of bone metastases
During metastatic dissemination, cancer cells from the primary tumor must first undergo epithelial-to-mesenchymal transition (EMT) to invade the surrounding tissue and enter the microvasculature (intravasation) of the blood and/or lymphatic systems. Once in the bloodstream, cancer cells may disseminate to distant organs, exit from blood vessels (extravasation), and settle in the foreign microenvironment, where they enter a dormant state or proliferate to subsequently form macroscopic secondary tumors (metastases) [7].
In the skeleton, the process of metastasis development begins with colonization, when circulating tumor cells enter the bone marrow and engage in specialized microenvironments or niches. Then, the colonizing tumor cells adapt to their new microenvironment, evade the immune system, and may reside in a dormant state for a long period of time until they reactivate and develop, escaping from the dormant state to actively proliferate and form micrometastases. With uncontrollable growth, the cancer cells become independent of the microenvironment and end up modifying the bone as metastases develop.
3. Type of bone metastases
In metastatic bone disease, the normal bone homeostasis that involves constant remodeling by the coordinated actions of osteoclasts and osteoblasts is disturbed [5, 7]. According to the primary mechanism of interference with normal bone remodeling, bone metastases can be classified as osteolytic, osteoblastic, or mixed [8].
If a lesion has both osteolytic and osteoblastic components, it’s classified as
4. Clinical presentation
Bone metastases may cause few or no symptoms, being diagnosed incidentally during the initial staging of the primary cancer. However, they can represent a prominent source of morbidity because of skeletal-related events (SREs), which include pain, pathologic fracture, spinal cord compression, and hypercalcemia [3, 5].
5. Diagnosis
Detection of bone metastases is essential for accurate staging and optimal treatment. There is no standard approach for the detection of bone metastases in patients with cancer, so the choice of imaging should be guided by the clinical presentation.
In general,
Whole-body skeletal evaluation with Tc-99 m
Definitive diagnosis requires histologic examination of
6. Treatment
Treatment goals may consist of controlling pain and other symptoms, preserving and restoring function, minimizing the risk of SREs, stabilizing the skeleton, and enhancing local tumor control. Therapeutic options include pain management/analgesia, osteoclast inhibitors, systemic anticancer therapy, radiation therapy, bone-targeting radiopharmaceutical therapy, surgery, and/or image-guided thermal ablation. The choice of treatment is influenced by factors like symptoms, impact on quality of life, performance status, estimated life expectancy, goals of treatment, and preferences of care. Optimal treatment may be complex and may require multimodality treatment strategies.
6.1 Analgesia
Patients with bone metastases will suffer from significant bone pain at some point of the disease course. Initially, for mild to moderate pain, nonopioid analgesic drugs, such as acetaminophen and nonsteroidal anti-inflammatory drugs (NSAIDs), may be used alone, but for moderate to severe pain, opioids should be the therapy of choice, according to the WHO “analgesic ladder” approach [19, 20].
Glucocorticoids may be helpful for selected patients as well as other adjuncts, like antidepressants and antiepileptics such as gabapentin [21, 22]. Actually, for patients with neurologic deficits or pain associated with spinal cord compression, high-dose glucocorticoid therapy is part of the standard treatment - a typical dose is 10 mg dexamethasone intravenously followed by 16 mg daily orally in divided doses, until definite treatment [23].
Multidisciplinary management with a palliative care specialist should be considered for patients whose pain is refractory to analgesia or who develop significant side effects.
6.2 Osteoclast inhibitors
For patients with metastatic bone disease, osteoclast inhibitors, like bisphosphonates and denosumab, may prevent SREs as they slow down or reverse the progression of skeletal metastases and may even improve pain and quality of life. For patients in whom SREs are unlikely (those with minimal bone tumor burden) or those with a limited expected survival, treatment with osteoclast inhibitors should be decided case by case.
There are two classes of bisphosphonates: nonnitrogen containing, such as etidronate, clodronate, and tiludronate, and nitrogen containing, such as pamidronate, alendronate, ibandronate, risedronate, and zoledronic acid, which are more potent osteoclast inhibitors [19]. When a bisphosphonate is chosen, zoledronic acid is suggested over other bisphosphonates.
If zoledronic acid is not available,
Bisphosphonates | Dosing | Interval |
---|---|---|
Zoledronic acid | 4 mg | 28/28 days |
Pamidronate | 90 mg | 28/28 days |
Ibandronate | 6 mg | 28/28 days |
Clodronate | 1600 mg | daily |
In terms of tolerance, nephrotoxicity is one of the most important side effects, which is both dose and infusion time dependent [5, 32]. Other common adverse effects include acute-phase reactions (with pyrexia and flu-like symptoms), gastrointestinal effects, and the most concerning, osteonecrosis of the jaw [5, 33].
6.3 Systemic anticancer therapy
Chemotherapy, targeted therapies, and hormone therapy may contribute to pain relief by reducing tumor bulk and/or by modulating pain signaling pathways [38]. In selecting systemic anticancer treatment for metastatic bone disease, the pathological type of the tumor is the most important [2].
6.4 Radiation therapy
Radiation therapy is commonly used in the management of bone metastases, both for pain relief and for the prevention of morbidity and disease progression [5].
6.5 Bone-targeting radiopharmaceutical therapy
Bone-targeted radiopharmaceuticals are radioactive bone-seeking molecules that show efficacy for pain control in patients with osteoblastic bone metastases, such as samarium-153, strontium-89, rhenium-186, and radium-223 [5].
6.6 Surgery
Surgical management of bone metastases is typically reserved for lesions with a complete or impending pathologic fracture or spine metastases that cause mechanical instability or spinal cord compression [5, 44]. Nonetheless, for highly selected patients with advanced cancer who present with or develop a bone lesion as the only focus of cancer beyond the primary site, resection of the bone metastasis may optimize local tumor control, provide durable pain relief, and possibly prolong survival.
6.7 Thermal ablation
For patients who have persistent or recurrent pain due to one or a few skeletal sites with small volume disease after palliative radiation therapy, and who are not candidates for surgery or reirradiation, local thermal ablation is an important therapeutic option. Radiofrequency ablation, microwave ablation, and cryoablation are effective ablative treatments for the palliation of symptomatic skeletal metastases [45, 46, 47, 48]. There are no randomized trials comparing these procedures, so the choice of ablation technique should take into account availability, patient preference, and local expertise.
7. Conclusion
Bone metastases are a common manifestation of distant relapse from many types of solid cancers, a significant source of morbidity, and a major contributor to the deterioration of the quality of life. Prompt diagnosis is essential for optimal treatment, which may consist of controlling pain and other symptoms, preserving and restoring function, minimizing the risk of SREs, stabilizing the skeleton, and enhancing local tumor control. This way, a multidisciplinary approach is essential to achieve the best outcome possible.
References
- 1.
Tubiana-Hulin M. Incidence, prevalence and distribution of bone metastases. Bone. 1991; 12 (SUPPL. 1):S9 - 2.
Coleman RE. Metastatic bone disease: Clinical features, pathophysiology and treatment strategies. Cancer Treatment Reviews. 2001; 27 (3):165-176 - 3.
Coleman RE, Roodman S, Body S, Vessella. Clinical features of metastatic bone disease and risk of skeletal morbidity. Clinical Cancer Research. 2006; 12 (20 PART 2):6243-6249 - 4.
Krishnamurthy GT, Tubis M, Hiss J, Blahd WH. Distribution pattern of metastatic bone disease: A need for Total Body skeletal image. JAMA The Journal of the American Medical Association. 1977; 237 (23):2504-2506 - 5.
Gralow JR, Biermann JS, Farooki A, Fornier MN, Gagel RF, Kumar RN, et al. NCCN task force report: Bone health in Cancer care. Journal of the National Comprehensive Cancer Network. 2009; 7 :S1-S35 - 6.
Schulman KL, Kohles J. Economic burden of metastatic bone disease in the U.S. Cancer. 2007; 109 (11):2334-2342 - 7.
Clézardin P, Coleman R, Puppo M, Ottewell P, Bonnelye E, Paycha F, et al. Bone metastasis: Mechanisms, therapies, and biomarkers. Physiological Reviews. 2021; 101 (3):797-855 - 8.
Macedo F, Ladeira K, Pinho F, Saraiva N, Bonito N, Pinto L, et al. Bone metastases: An overview. Oncology Reviews. 2017; 11 :1 - 9.
Clohisy DR, Mantyh PW. Bone cancer pain. Cancer. 2003; 97 (3 SUPPL):866-873 - 10.
Selvaggi G, Scagliotti GV. Management of bone metastases in cancer: A review. Critical Reviews in Oncology/Hematology. 2005; 56 (3):365-378 - 11.
Helweg-Larsen S, Sørensen PS. Symptoms and signs in metastatic spinal cord compression: A study of progression from first symptom until diagnosis in 153 patients. European Journal of Cancer. 1994; 30 (3):396-398 - 12.
Maisano R, Pergolizzi S, Cascinu S. Novel therapeutic approaches to cancer patients with bone metastasis. Critical Reviews in Oncology/Hematology. 2001; 40 (3):239-250 - 13.
Coleman R, Hadji P, Body JJ, Santini D, Chow E, Terpos E, et al. Bone health in cancer: ESMO clinical practice guidelines. Annals of Oncology. 2020; 31 (12):1650-1663 - 14.
Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. Journal of Clinical Oncology. 2004; 22 (14):2942-2953 - 15.
Yang HL, Liu T, Wang XM, Xu Y, Deng SM. Diagnosis of bone metastases: A meta-analysis comparing 18FDG PET, CT, MRI and bone scintigraphy. European Radiology. 2011; 21 (12):2604-2617 - 16.
Liu T, Wang S, Liu H, Meng B, Zhou F, He F, et al. Detection of vertebral metastases: A meta-analysis comparing MRI, CT, PET, BS and BS with SPECT. Journal of Cancer Research and Clinical Oncology. 2017; 143 (3):457-465 - 17.
Algra PR, Bloem JL, Tissing H, Falke TH, Arndt JW, Verboom LJ. Detection of vertebral metastases: Comparison between MR imaging and bone scintigraphy. Radiographics. 1991; 11 (2):219-232 - 18.
Monfardini L, Preda L, Aurilio G, Rizzo S, Bagnardi V, Renne G, et al. CT-guided bone biopsy in cancer patients with suspected bone metastases: Retrospective review of 308 procedures. La Radiologia Medica. 2014; 119 (11):852-860 - 19.
Buga S, Sarria JE. The management of pain in metastatic bone disease. Cancer Control. 2012; 19 (2):154-166 - 20.
Portenoy RK, Lesage P. Management of cancer pain. Lancet. 1999; 353 (9165):1695-1700 - 21.
Hardy JR, Jenkins-Marsh S, Pinkerton E, Rickett K, Good P. Corticosteroids for the management of cancer-related pain in adults. Cochrane Database of Systematic Reviews. 2013; 2013 (10):1-42 - 22.
Portenoy RK. A practical approach to using adjuvant analgesics in older adults. Journal of the American Geriatrics Society. 2020; 68 (4):691-698 - 23.
Kumar A, Weber MH, Gokaslan Z, Wolinsky JP, Schmidt M, Rhines L, et al. Metastatic spinal cord compression and steroid treatment: A systematic review. Clinical Spine Surgery. 2017; 30 (4):156-163 - 24.
Kohno N, Aogi K, Minami H, Nakamura S, Asaga T, Iino Y, et al. Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: A randomized, placebo-controlled trial. Journal of Clinical Oncology. 2005; 23 (15):3314-3321 - 25.
Berenson JR, Rosen LS, Howell A, Porter L, Coleman RE, Morley W, et al. Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases: A double-blind, randomized dose-response study. Cancer. 2001; 91 (7):1191-1200 - 26.
Tu SM, Lin SH, Logothetis C, Saad F. A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma. Journal of the National Cancer Institute. 2003; 95 (15):1174-1175 - 27.
Rosen LS, Gordon D, Tchekmedyian NS, Yanagihara R, Hirsh V, Krzakowski M, et al. Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: A randomized, phase III, double-blind, placebo-controlled trial. Cancer. 2004; 100 (12):2613-2621 - 28.
Hatoum HT, Lin SJ, Smith MR, Barghout V, Lipton A. Zoledronic acid and skeletal complications in patients with solid tumors and bone metastases. Cancer. 2008; 113 (6):1438-1445 - 29.
Rosen LS, Gordon D, Tchekmedyian S, Yanagihara R, Hirsh V, Krzakowski M, et al. Zoledronic acid versus placebo in the treatment of skeletal metastases in patients with lung cancer and other solid tumors: A phase III, double-blind, randomized trial - the zoledronic acid lung cancer and other solid tumors study group. Journal of Clinical Oncology. 2003; 21 (16):3150-3157 - 30.
Kristensen B, Ejlertsen B, Groenvold M, Hein S, Loft H, Mouridsen HT. Oral clodronate in breast cancer patients with bone metastases: A randomized study. Journal of Internal Medicine. 1999; 246 (1):67-74 - 31.
Body JJ, Diel IJ, Liehinitzer M, Lazarev A, Pecherstorfer M, Bell R, et al. Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: Results from two randomised, placebo-controlled phase III studies. British Journal of Cancer. 2004; 90 (6):1133-1137 - 32.
Perazella MA, Markowitz GS. Bisphosphonate nephrotoxicity. Kidney International. 2008; 74 (11):1385-1393 - 33.
Diel IJ, Bergner R, Grötz KA. Adverse effects of bisphosphonates: Current issues. The Journal of Supportive Oncology. 2007; 5 (10):475-482 - 34.
Stopeck AT, Lipton A, Body JJ, Steger GG, Tonkin K, De Boer RH, et al. Denosumab compared with zoledronic acid for the treatment of bone metastases in patients with advanced breast cancer: A randomized, double-blind study. Journal of Clinical Oncology. 2010; 28 (35):5132-5139 - 35.
Fizazi K, Carducci M, Smith M, Damião R, Brown J, Karsh L, et al. Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: A randomised, double-blind study. Lancet. 2011; 377 (9768):813-822 - 36.
Henry DH, Costa L, Goldwasser F, Hirsh V, Hungria V, Prausova J, et al. Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma. Journal of Clinical Oncology. 2011; 29 (9):1125-1132 - 37.
Lipton A, Fizazi K, Stopeck AT, Henry DH, Brown JE, Yardley DA, et al. Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: A combined analysis of 3 pivotal, randomised, phase 3 trials. European Journal of Cancer. 2012; 48 (16):3082-3092 - 38.
Gough N, Miah AB, Linch M. Nonsurgical oncological management of cancer pain. Current Opinion in Supportive and Palliative Care. 2014; 8 (2):102-111 - 39.
Chow E, Harris K, Fan G, Tsao M, Sze WM. Palliative radiotherapy trials for bone metastases: A systematic review. Journal of Clinical Oncology. 2007; 25 (11):1423-1436 - 40.
Lutz S, Berk L, Chang E, Chow E, Hahn C, Hoskin P, et al. Palliative radiotherapy for bone metastases: An ASTRO evidence-based guideline. International Journal of Radiation Oncology, Biology, Physics. 2011; 79 (4):965-976 - 41.
Gerszten PC, Burton SA, Ozhasoglu C, Welch WC. Radiosurgery for spinal metastases: Clinical experience in 500 cases from a single institution. Spine (Phila Pa 1976). 2007; 32 (2):193-199 - 42.
Palma DA, Olson R, Harrow S, Gaede S, Louie AV, Haasbeek C, et al. Stereotactic ablative radiotherapy versus standard of care palliative treatment in patients with oligometastatic cancers (SABR-COMET): A randomised, phase 2, open-label trial. Lancet. 2019; 393 (10185):2051-2058 - 43.
Sartor O, Coleman R, Nilsson S, Heinrich D, Helle SI, O’Sullivan JM, et al. Effect of radium-223 dichloride on symptomatic skeletal events in patients with castration-resistant prostate cancer and bone metastases: Results from a phase 3, double-blind, randomised trial. The Lancet Oncology. 2014; 15 (7):738-746 - 44.
Wood TJ, Racano A, Yeung H, Farrokhyar F, Ghert M, Deheshi BM. Surgical Management of Bone Metastases: Quality of evidence and systematic review. Annals of Surgical Oncology. 2014; 21 (13):4081-4089 - 45.
McMenomy BP, Kurup AN, Johnson GB, Carter RE, McWilliams RR, Markovic SN, et al. Percutaneous cryoablation of musculoskeletal oligometastatic disease for complete remission. Journal of Vascular and Interventional Radiology. 2013; 24 (2):207-213 - 46.
Tomasian A, Wallace A, Northrup B, Hillen TJ, Jennings JW. Spine cryoablation: Pain palliation and local tumor control for vertebral metastases. American Journal of Neuroradiology. 2016; 37 (1):189-195 - 47.
Deschamps F, Farouil G, Ternes N, Gaudin A, Hakime A, Tselikas L, et al. Thermal ablation techniques: A curative treatment of bone metastases in selected patients? European Radiology. 2014; 24 (8):1971-1980 - 48.
Winkelmann MT, Clasen S, Pereira PL, Hoffmann R. Local treatment of oligometastatic disease: Current role. The British Journal of Radiology. 2019; 92 (1100):1-10